CHNQD-01255
CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy.
For research use only. We do not sell to patients.
- CAS No.: 2756173-91-6
- Formula: C23H29NO6
- Molecular Weight:415.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bel-7402 | IC50 |
0.07 μM
Compound: 16; CHNQD-01255
|
Antiproliferative activity against human Bel-7402 cells by MTT assay
Antiproliferative activity against human Bel-7402 cells by MTT assay
|
[PMID: 36089748] |
| HepG2 | IC50 |
0.1 μM
Compound: 16; CHNQD-01255
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 36089748] |
In Vitro
CHNQD-01255 (0-1 μM approximately, 72 h) inhibits HepG2 and BEL-7402 cell proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2, BEL-7402 cell
-
Concentration:0-1 μM approximately
-
Incubation Time:72 h
-
Result:Inhibited cell proliferation with an IC50 value of 0.1 μM (HepG2) and 0.07 μM (BEL-7402).
In Vivo
CHNQD-01255 exhibits a high safety profile with MTD values exceeding 750 and 100 mg/kg for p.o. and i.p. administrations in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HepG2 tumor-bearing xenograft mice[1]
-
Dosage:5, 15, and 45 mg/kg
-
Administration:Oral adminstration (p.o.), every day for 21 consecutive days.
-
Result:Resulted in dramatically delayed tumor progression, with a tumor growth inhibition rate (TGI %) value of 61.0% at 45 mg/kg.
-
Animal Model:HepG2 tumor-bearing xenograft mice[1]
-
Dosage:1 and 9 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every day for 21 consecutive days.
-
Result:Inhibited the tumor growth with the TGI values of 36.6 and 48.3%, respectively.
-
Animal Model:Mice (Pharmacokinetic assay)[1]
-
Dosage:45 mg/kg p.o., 10 mg/kg i.v.
-
Administration:Oral adminstration (p.o.) or intravenous injection (i.v.)
-
Result:Pharmacokinetic profile of CHNQD-01255.
dose (mg/kg) T1/2 (h) Cmax (ng/mL) Cl (mL/h/kg) F (%) 45 (p.o.) 7.35 20.26 598245.37 2.26 10 (i.v.) 2060.78
Chemical Information
-
CAS No. 2756173-91-6
-
Molecular Weight 415.48
-
Formula C23H29NO6
-
SMILES
O[C@H]1[C@@]2([H])[C@@](/C=C/CCC[C@@H](OC(/C=C/1)=O)C)([H])C[C@@H](C2)OC(OCC3=CN=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CHNQD-01255 Related Classifications
HY-151461 Related Classifications
Powered by Bioz